1. Patents in multiple countries have expired.
2. Head-to-head trial failed.
3. GLP-1 drugs face massive price cuts in US Medicare.
What other horror stories are there? Market makers, post a few more.$Novo Nordisk AS(NVO.US)
$Novo Nordisk AS(NVO.US)
NVO is given a historically ultra-low valuation of 18x P/E, with an expected EPS of 3.3, implying a fair value of 60. Targeting a 50% return in 12 months means entry at 40 dollars. From a technical perspective, it's currently at the 0.236 Fibonacci retracement level of the entire wave starting from the 2009 period, and also at the 1/8 line of the wave starting from 2017, forming a very strong support level. You can refer to the UPS trend. If 35.8 is the bottom, then drawing the Fibonacci from the high and low points, the 0.236 level is 62, which is also the level UPS reached. Currently, the fundamental valuation has formed a super resonance with the technicals.
Buy at the current price of 40, target 60.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
